Related Experiment Video

Updated: Jun 4, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer

Elvira Avilla1, Valentina Guarino, Carla Visciano

  • 1Dipartimento di Biologia e Patologia Cellulare e Molecolare/Istituto di Endocrinologia ed Oncologia Sperimentale del CNR G. Salvatore, Naples, Italy.

Cancer Research
|February 24, 2011
PubMed

Insights

Researchers identified the TYRO3 and AXL receptor tyrosine kinases as key drivers in thyroid cancer. Targeting the TYRO3/AXL-GAS6 circuit may offer a novel therapeutic strategy for this common endocrine cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Thyroid cancer is the most common endocrine malignancy.
  • Key oncogenic drivers in thyroid cancer are not fully understood.
  • Receptor tyrosine kinases play crucial roles in cancer development.

Purpose of the Study:

  • To identify novel oncogenic drivers in thyroid cancer.
  • To investigate the role of TYRO3 and AXL receptor tyrosine kinases in thyroid cancer.
  • To explore the potential of targeting the TYRO3/AXL-GAS6 pathway as a therapeutic strategy.

Main Methods:

  • Analysis of gene expression in thyroid cancer cell lines and human specimens.
  • Investigating the function of TYRO3, AXL, and GAS6 using cell-based assays.
  • Utilizing siRNA-mediated gene silencing and tumor xenograft models in mice.

Main Results:

  • TYRO3 and AXL were identified as transcriptional targets of CXCL12/SDF-1 in CXCR4-expressing thyroid cancer cells.
  • AXL and its ligand GAS6 were constitutively expressed and coexpressed in thyroid cancer tissues but not normal tissues.
  • Blocking the TYRO3/AXL-GAS6 pathway significantly reduced cancer cell viability, proliferation, invasiveness, and tumor growth.

Conclusions:

  • A TYRO3/AXL-GAS6 autocrine circuit sustains the malignant characteristics of thyroid cancer cells.
  • Targeting this circuit presents a promising novel therapeutic approach for thyroid cancer.
  • Further research into this pathway could lead to effective treatments for endocrine cancers.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...